Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Moderna says cooperating with CDPH in probe of reports of adverse vaccine events » 12:52
01/19/21
01/19
12:52
01/19/21
12:52
MRNA

Moderna

$123.33 /

-6.27 (-4.84%)

Moderna stated that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$123.33 /

-6.27 (-4.84%)

MRNA Moderna
$123.33 /

-6.27 (-4.84%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
MRNA Moderna
$123.33 /

-6.27 (-4.84%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$123.33 /

-6.27 (-4.84%)

MRNA Moderna
$123.33 /

-6.27 (-4.84%)

MRNA Moderna
$123.33 /

-6.27 (-4.84%)

Options
Largest borrow rate increases among liquid names » 08:45
01/19/21
01/19
08:45
01/19/21
08:45
GME

GameStop

$35.41 /

-4.42 (-11.10%)

, WBAI

500.com

$13.53 /

-0.145 (-1.06%)

, BNTX

BioNTech

$101.54 /

-4.19 (-3.96%)

, GNOG

Golden Nugget Online

$20.84 /

-1.08 (-4.93%)

, PLG

Platinum Group

$4.36 /

-0.385 (-8.12%)

, CVM

CEL-SCI

$14.30 /

+0.9 (+6.72%)

, VUZI

Vuzix

$8.96 /

-0.515 (-5.44%)

, IDEX

Ideanomics

$3.17 /

-0.12 (-3.65%)

, EOSE

Eos Energy Enterprises

$23.03 /

-1.525 (-6.21%)

, WISH

ContextLogic

$24.84 /

-3.21 (-11.44%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: GameStop (GME) 54.15% +23.38, 500.com (WBAI) 236.19% +14.67, BioNTech SE (BNTX) 28.64% +10.50, (GNOG) 10.42% +7.63, Platinum Group (PLG) 40.92% +6.84, Cel Sci (CVM) 71.20% +6.17, Vuzix (VUZI) 48.96% +4.89, Ideanomics (IDEX) 24.77% +3.71, B Riley Principal Merger Corp II (EOSE) 33.59% +3.68, and ContextLogic (WISH) 14.48% +3.51.

ShowHide Related Items >><<
WBAI 500.com
$13.53 /

-0.145 (-1.06%)

VUZI Vuzix
$8.96 /

-0.515 (-5.44%)

IDEX Ideanomics
$3.17 /

-0.12 (-3.65%)

GME GameStop
$35.41 /

-4.42 (-11.10%)

EOSE Eos Energy Enterprises
$23.03 /

-1.525 (-6.21%)

CVM CEL-SCI
$14.30 /

+0.9 (+6.72%)

BNTX BioNTech
$101.54 /

-4.19 (-3.96%)

GME GameStop
$35.41 /

-4.42 (-11.10%)

01/13/21 Standpoint Research
GameStop downgraded to Hold from Buy at Standpoint Research
01/11/21 Benchmark
Benchmark 'not surprised' by GameStop board change after 'disappointing' holiday
12/09/20 Benchmark
GameStop price target lowered to $5 from $6 at Benchmark
12/04/20 Wedbush
GameStop price target raised to $16 from $8 at Wedbush
WBAI 500.com
$13.53 /

-0.145 (-1.06%)

BNTX BioNTech
$101.54 /

-4.19 (-3.96%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
GNOG Golden Nugget Online
$20.84 /

-1.08 (-4.93%)

01/13/21 Benchmark
Golden Nugget Online initiated with a Buy at Benchmark
PLG Platinum Group
$4.36 /

-0.385 (-8.12%)

CVM CEL-SCI
$14.30 /

+0.9 (+6.72%)

05/14/20 H.C. Wainwright
CEL-SCI price target raised to $23 from $18 at H.C. Wainwright
VUZI Vuzix
$8.96 /

-0.515 (-5.44%)

08:10 Today Maxim
Vuzix price target raised to $13 from $6.50 at Maxim
09/04/20 Craig-Hallum
Vuzix price target raised to $8 from $6 at Craig-Hallum
05/11/20 Alliance Global Partners
Vuzix downgraded to Neutral from Buy at Alliance Global Partners
IDEX Ideanomics
$3.17 /

-0.12 (-3.65%)

EOSE Eos Energy Enterprises
$23.03 /

-1.525 (-6.21%)

01/15/21 B. Riley Securities
Eos Energy Enterprises price target raised to $35 from $23 at B. Riley
12/10/20 B. Riley Securities
Eos Energy Enterprises price target raised to $22 from $17 at B. Riley Securities
11/20/20
Fly Intel: Top five analyst initiations
11/20/20 B. Riley Securities
Eos Energy Enterprises initiated with a Buy at B. Riley Securities
WISH ContextLogic
$24.84 /

-3.21 (-11.44%)

01/11/21 JPMorgan
ContextLogic initiated with an Overweight at JPMorgan
01/11/21 UBS
ContextLogic initiated with a Buy at UBS
01/11/21 Credit Suisse
ContextLogic initiated with an Outperform at Credit Suisse
01/11/21 Loop Capital
ContextLogic initiated with a Hold at Loop Capital
VUZI Vuzix
$8.96 /

-0.515 (-5.44%)

IDEX Ideanomics
$3.17 /

-0.12 (-3.65%)

GME GameStop
$35.41 /

-4.42 (-11.10%)

BNTX BioNTech
$101.54 /

-4.19 (-3.96%)

  • 16
    Dec
  • 23
    Jul
  • 06
    Feb
WISH ContextLogic
$24.84 /

-3.21 (-11.44%)

WBAI 500.com
$13.53 /

-0.145 (-1.06%)

VUZI Vuzix
$8.96 /

-0.515 (-5.44%)

GME GameStop
$35.41 /

-4.42 (-11.10%)

EOSE Eos Energy Enterprises
$23.03 /

-1.525 (-6.21%)

CVM CEL-SCI
$14.30 /

+0.9 (+6.72%)

BNTX BioNTech
$101.54 /

-4.19 (-3.96%)

WISH ContextLogic
$24.84 /

-3.21 (-11.44%)

WBAI 500.com
$13.53 /

-0.145 (-1.06%)

IDEX Ideanomics
$3.17 /

-0.12 (-3.65%)

GME GameStop
$35.41 /

-4.42 (-11.10%)

EOSE Eos Energy Enterprises
$23.03 /

-1.525 (-6.21%)

BNTX BioNTech
$101.54 /

-4.19 (-3.96%)

WISH ContextLogic
$24.84 /

-3.21 (-11.44%)

VUZI Vuzix
$8.96 /

-0.515 (-5.44%)

PLG Platinum Group
$4.36 /

-0.385 (-8.12%)

IDEX Ideanomics
$3.17 /

-0.12 (-3.65%)

GME GameStop
$35.41 /

-4.42 (-11.10%)

EOSE Eos Energy Enterprises
$23.03 /

-1.525 (-6.21%)

CVM CEL-SCI
$14.30 /

+0.9 (+6.72%)

BNTX BioNTech
$101.54 /

-4.19 (-3.96%)

Recommendations
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG » 06:48
01/19/21
01/19
06:48
01/19/21
06:48
ADPT

Adaptive Biotechnologies

$64.95 /

-0.66 (-1.01%)

, AZN

AstraZeneca

$51.35 /

+0.05 (+0.10%)

BTIG analyst Mark Massaro…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

ADPT Adaptive Biotechnologies
$64.95 /

-0.66 (-1.01%)

ADPT Adaptive Biotechnologies
$64.95 /

-0.66 (-1.01%)

12/17/20 BTIG
BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks'
11/12/20 BTIG
Adaptive Biotechnologies price target raised to $63 from $60 at BTIG
11/11/20 JPMorgan
Adaptive Biotechnologies price target raised to $60 from $50 at JPMorgan
10/07/20 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

ADPT Adaptive Biotechnologies
$64.95 /

-0.66 (-1.01%)

  • 16
    Jul
  • 24
    Jan
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

ADPT Adaptive Biotechnologies
$64.95 /

-0.66 (-1.01%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

Yesterday
Periodicals
NY Gov. asks Pfizer to directly sell COVID vaccine doses, Reuters reports » 17:19
01/18/21
01/18
17:19
01/18/21
17:19
PFE

Pfizer

$36.70 /

-0.05 (-0.14%)

New York Governor Andrew…

New York Governor Andrew Cuomo asked Pfizer Inc Chief Executive Albert Bourla on Monday if the state could buy COVID-19 vaccine doses directly from the U.S. drugmaker, Reuters' Kanishka Singh reports. Pfizer, however, told Reuters that such a proposal would first require approval by the U.S. Department of Health and Human Services. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

Hot Stocks
AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer » 12:58
01/18/21
01/18
12:58
01/18/21
12:58
AZN

AstraZeneca

$51.35 /

+0.05 (+0.10%)

AstraZeneca and Daiichi…

AstraZeneca and Daiichi Sankyo said Enhertu has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. The approval by the Food and Drug Administration was based on the positive results from the randomized DESTINY-Gastric01 Phase II trial conducted in Japan and South Korea. Enhertu is approved with Boxed Warnings for interstitial lung disease or pneumonitis and embryo-fetal toxicity. This is the second indication approved for Enhertu in the U.S. following the accelerated approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting based on the DESTINY-Breast01 trial.

ShowHide Related Items >><<
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

Sunday
Periodicals
Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says » 17:18
01/17/21
01/17
17:18
01/17/21
17:18
AZN

AstraZeneca

$51.35 /

+0.05 (+0.10%)

AstraZeneca's…

AstraZeneca's COVID-19 vaccine has been approved for emergency use in Pakistan, the health minister said, making it the first coronavirus vaccine to get the green light for use in the South Asian country, Reuters' Asif Shahzad reports. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

Friday
Recommendations
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg » 14:26
01/15/21
01/15
14:26
01/15/21
14:26
AZN

AstraZeneca

$51.35 /

+0.05 (+0.10%)

Berenberg analyst Luisa…

Berenberg analyst Luisa Hector lowered the firm's price target on AstraZeneca to 10,000 GBp from 10,500 GBp and keeps a Buy rating on the shares.

ShowHide Related Items >><<
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/30/20
Fly Intel: Top five analyst calls
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

Initiation
Fly Intel: Top five analyst initiations » 09:52
01/15/21
01/15
09:52
01/15/21
09:52
AZN

AstraZeneca

$51.47 /

+0.17 (+0.33%)

, ALLK

Allakos

$129.75 /

+1.18 (+0.92%)

, SKLZ

Skillz

$25.91 /

-0.13 (-0.50%)

, PLAN

Anaplan

$71.68 /

+1.025 (+1.45%)

, ATI

Allegheny Technologies

$18.11 /

-0.48 (-2.58%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AstraZeneca (AZN) initiated with a Buy at Deutsche Bank. 2. Allakos (ALLK) initiated with a Buy at BofA. 3. Skillz (SKLZ) initiated with an Equal Weight at Wells Fargo. 4. Anaplan initiated with an Outperform rating at William Blair. 5. Allegheny Technologies (ATI) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
PLAN Anaplan
$71.68 /

+1.025 (+1.45%)

AZN AstraZeneca
$51.47 /

+0.17 (+0.33%)

ATI Allegheny Technologies
$18.11 /

-0.48 (-2.58%)

ALLK Allakos
$129.75 /

+1.18 (+0.92%)

AZN AstraZeneca
$51.47 /

+0.17 (+0.33%)

01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/30/20
Fly Intel: Top five analyst calls
12/30/20 AlphaValue
AlphaValue upgrades AstraZeneca, sees sentiment 'finally' improving
ALLK Allakos
$129.75 /

+1.18 (+0.92%)

01/15/21 BofA
Allakos initiated with a Buy at BofA
12/21/20 SVB Leerink
SVB Leerink bullish on Allakos, initiates with an Outperform
12/21/20 SVB Leerink
Allakos initiated with an Outperform at SVB Leerink
03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
SKLZ Skillz
$25.91 /

-0.13 (-0.50%)

01/15/21 Wells Fargo
Skillz initiated with an Equal Weight at Wells Fargo
01/12/21 Wedbush
Skillz initiated with an Outperform at Wedbush
01/12/21
Fly Intel: Top five analyst initiations
01/12/21 Stifel
Skillz initiated with a Buy at Stifel
PLAN Anaplan
$71.68 /

+1.025 (+1.45%)

01/15/21 William Blair
Blair starts Anaplan at Outperform, calls attractive acquisition target
01/11/21 Piper Sandler
Anaplan upgraded to Overweight from Neutral at Piper Sandler
01/11/21 Jefferies
Anaplan upgraded to Buy from Hold at Jefferies
01/05/21 Wells Fargo
Anaplan upgraded to Overweight from Equal Weight at Wells Fargo
ATI Allegheny Technologies
$18.11 /

-0.48 (-2.58%)

01/15/21 Seaport Global
Allegheny Technologies initiated with a Buy at Seaport Global
12/07/20 KeyBanc
Allegheny Technologies price target raised to $25 from $15 at KeyBanc
12/04/20
Fly Intel: Top five analyst upgrades
12/04/20 Benchmark
Benchmark upgrades Allegheny Technologies to Buy after commodity stainless exit
PLAN Anaplan
$71.68 /

+1.025 (+1.45%)

AZN AstraZeneca
$51.47 /

+0.17 (+0.33%)

ATI Allegheny Technologies
$18.11 /

-0.48 (-2.58%)

ALLK Allakos
$129.75 /

+1.18 (+0.92%)

  • 29
    Oct
  • 13
    May
AZN AstraZeneca
$51.47 /

+0.17 (+0.33%)

PLAN Anaplan
$71.68 /

+1.025 (+1.45%)

AZN AstraZeneca
$51.47 /

+0.17 (+0.33%)

AZN AstraZeneca
$51.47 /

+0.17 (+0.33%)

Hot Stocks
Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial » 08:20
01/15/21
01/15
08:20
01/15/21
08:20
AVEO

Aveo Pharmaceuticals

$8.23 /

+0.23 (+2.88%)

, AZN

AstraZeneca

$51.30 /

+0.4 (+0.79%)

Aveo Oncology (AVEO)…

Aveo Oncology (AVEO) announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib, Aveo's vascular endothelial growth factor receptor tyrosine kinase inhibitor, or TKI, drug candidate, in combination with Imfinzi, AstraZeneca's (AZN) human monoclonal antibody directed against programmed death-ligand 1, or PD-L1, in patients with advanced or metastatic hepatocellular carcinoma, or HCC. The results are being presented in a poster session at the 2021 American Society of Clinical Oncology Gastrointestinal, or ASCO GI, Cancers Symposium being held virtually. A total of seven patients with advanced or metastatic HCC were enrolled in the Phase 1b portion of the study, which was designed to determine the recommended Phase 2 dose and assess preliminary safety and efficacy of the tivozanib/durvalumab combination. Patients received 1.0 mg of tivozanib for 21 days followed by 7 days off therapy combined with 1500 mg of durvalumab every 28 days. The combination was well tolerated, with no dose-limiting toxicities. The combination demonstrated a 29% partial response rate and 71% disease control rate. Completion of enrollment in the ongoing Phase 2 portion of the study, which is expected to enroll up to an additional 30 subjects, is anticipated later this year.

ShowHide Related Items >><<
AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AVEO Aveo Pharmaceuticals
$8.23 /

+0.23 (+2.88%)

AVEO Aveo Pharmaceuticals
$8.23 /

+0.23 (+2.88%)

11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Stifel
Aveo Pharmaceuticals initiated with a Buy at Stifel
08/13/20 SVB Leerink
SVB Leerink bullish on Aveo Pharmaceuticals, initiates with an Outperform
08/13/20 SVB Leerink
Aveo Pharmaceuticals initiated with an Outperform at SVB Leerink
AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/30/20
Fly Intel: Top five analyst calls
12/30/20 AlphaValue
AlphaValue upgrades AstraZeneca, sees sentiment 'finally' improving
AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AVEO Aveo Pharmaceuticals
$8.23 /

+0.23 (+2.88%)

  • 17
    Jun
AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AVEO Aveo Pharmaceuticals
$8.23 /

+0.23 (+2.88%)

AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

Periodicals
AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports » 07:53
01/15/21
01/15
07:53
01/15/21
07:53
AZN

AstraZeneca

$51.30 /

+0.4 (+0.79%)

Nepal granted approval…

Nepal granted approval for AstraZeneca's COVISHIELD vaccine against the coronavirus, Reuters' Gopal Sharma and Alasdair Pal report, citing the government. The approval follows a meeting with neighboring India, a major manufacturer of the shot, the report noted. "Conditional permission has been granted for emergency use authorization of COVISHIELD vaccine against COVID-19 in Nepal," the Department of Drug Administration said. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/30/20
Fly Intel: Top five analyst calls
12/30/20 AlphaValue
AlphaValue upgrades AstraZeneca, sees sentiment 'finally' improving
AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

AZN AstraZeneca
$51.30 /

+0.4 (+0.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.